Given these findings, ANXA1 holds potential as a valuable biomarker for prognostication in BLCA patients, offering insights into the development of precise and personalized therapeutic strategies for BLCA in the future. This evidence concerns the gene ANXA1 and bladder transitional cell carcinoma.